首页 > 最新文献

Journal of Arrhythmia最新文献

英文 中文
Letter to the Editor Regarding “Impact of Anisotropic Conduction and Premature Atrial Contraction on the Fractionated Atrial Potentials” 关于“各向异性传导和过早心房收缩对分房电位的影响”的致编辑信。
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-30 DOI: 10.1002/joa3.70262
Hamza Ibrahim, Laraib Riaz, Muqeet Hasnain

We read with interest the article titled “Impact of anisotropic conduction and premature atrial contraction on the fractionated atrial potentials” [1]. They report that premature atrial contractions (PACs) shift fractionated atrial potentials (FAPs) away from the right and mid anterior walls toward the left anterior, left inferior, and lateral walls, emphasizing the impact of extrastimuli direction on atrial substrate characterization.

In contrast, Heida et al., using intraoperative high-resolution epicardial mapping during spontaneous PACs in 228 patients, found no clear increase in conduction heterogeneity or fractionation in regions like Bachmann's bundle or pulmonary vein area that would support a substantial PAC-induced FAP burden [2]. Their quantification of local directional heterogeneity revealed that while PACs modestly increased LDH, they did so uniformly and did not reproduce the dramatic regional redistribution seen by Toyama and Kumagai. This raises the question of whether PACs truly alter FAP distribution in the manner proposed by the recent study.

Moreover, Hirokami et al. studied fractionated signal areas in the atrial muscle during pacing and premature extrasystoles and concluded that the effect of premature stimuli direction on fractionation patterns was minimal, suggesting that the directionality emphasized by Toyama and Kumagai may be overinterpreted [3].

A further layer of contradiction comes from two additional studies. Teuwen et al. [4] used high-resolution epicardial mapping to compare conduction during sinus rhythm and atrial extrasystoles (AES) in over 160 patients; they found that decreases in conduction velocity and increases in delay occurred primarily in cases of aberrant wavefronts or breakthrough AES, but the degree of prematurity itself did not consistently correlate with increased conduction block or fractionation, indicating that not all PACs cause enhanced FAP burden [4]. Additionally, modeling and optical mapping work in canine atria by Roberts-Thomson et al. demonstrated that anisotropic conduction properties and resulting fractionated electrograms were highly dependent on tissue structural geometry and pacing rate rather than PAC direction per se—suggesting a more complex interplay than Toyama and Kumagai's direction-based hypothesis allows [5].

Taken together, these contradictory findings highlight that while Toyama and Kumagai's work provides valuable insight into how anisotropic conduction and extrastimuli may affect FAP distribution, other clinical and modeling data challenge the magnitude and regional specificity of those effects—emphasizing the need for standardized high-density mapping and controlled comparisons between spontaneous and paced PACs to resolve these discrepancies.

The authors declare no conflicts of interest.

我们饶有兴趣地阅读了题为“各向异性传导和早衰心房收缩对分房电位的影响”的文章。他们报告说,早衰心房收缩(PACs)使分异心房电位(FAPs)从右前壁和中前壁转移到左前壁、左下壁和侧壁,强调了外刺激方向对心房底物特征的影响。相比之下,Heida等人在228例自发性PACs患者中使用术中高分辨率心外膜测图,发现巴赫曼束或肺静脉等区域的传导不均匀性或分异性没有明显增加,而这些区域可能支持pac诱导的FAP负担bbb。他们对局部定向异质性的量化表明,尽管pac适度地增加了LDH,但它们是均匀的,并且没有重现Toyama和Kumagai所看到的戏剧性的区域再分配。这就提出了一个问题,即pac是否真的像最近研究提出的那样改变FAP分布。此外,Hirokami等人研究了起搏和早搏时心房肌的分步信号区,并得出结论,早搏刺激方向对分步信号模式的影响很小,这表明Toyama和Kumagai所强调的方向性可能被过度解释了[3]。另一层矛盾来自另外两项研究。Teuwen等人([4])使用高分辨率心外膜测图比较160多例患者窦性心律和房性心动过速(AES)时的传导;他们发现,传导速度的降低和延迟的增加主要发生在异常波前或突破AES的情况下,但早产程度本身并不总是与传导阻滞或分异增加相关,这表明并非所有pac都会导致FAP负担加重。此外,Roberts-Thomson等人在犬心房中进行的建模和光学测绘工作表明,各向异性传导特性和由此产生的分形电图高度依赖于组织结构几何形状和起搏速率,而不是PAC方向本身,这表明[5]的相互作用比Toyama和Kumagai基于方向的假设所允许的更为复杂。总的来说,这些相互矛盾的发现突出表明,虽然Toyama和Kumagai的工作为各向异性传导和外刺激如何影响FAP分布提供了有价值的见解,但其他临床和建模数据对这些影响的大小和区域特异性提出了挑战,强调需要标准化的高密度映射和自发PACs与节奏PACs之间的受控比较来解决这些差异。作者声明无利益冲突。
{"title":"Letter to the Editor Regarding “Impact of Anisotropic Conduction and Premature Atrial Contraction on the Fractionated Atrial Potentials”","authors":"Hamza Ibrahim,&nbsp;Laraib Riaz,&nbsp;Muqeet Hasnain","doi":"10.1002/joa3.70262","DOIUrl":"10.1002/joa3.70262","url":null,"abstract":"<p>We read with interest the article titled “Impact of anisotropic conduction and premature atrial contraction on the fractionated atrial potentials” [<span>1</span>]. They report that premature atrial contractions (PACs) shift fractionated atrial potentials (FAPs) away from the right and mid anterior walls toward the left anterior, left inferior, and lateral walls, emphasizing the impact of extrastimuli direction on atrial substrate characterization.</p><p>In contrast, Heida et al., using intraoperative high-resolution epicardial mapping during spontaneous PACs in 228 patients, found no clear increase in conduction heterogeneity or fractionation in regions like Bachmann's bundle or pulmonary vein area that would support a substantial PAC-induced FAP burden [<span>2</span>]. Their quantification of local directional heterogeneity revealed that while PACs modestly increased LDH, they did so uniformly and did not reproduce the dramatic regional redistribution seen by Toyama and Kumagai. This raises the question of whether PACs truly alter FAP distribution in the manner proposed by the recent study.</p><p>Moreover, Hirokami et al. studied fractionated signal areas in the atrial muscle during pacing and premature extrasystoles and concluded that the effect of premature stimuli direction on fractionation patterns was minimal, suggesting that the directionality emphasized by Toyama and Kumagai may be overinterpreted [<span>3</span>].</p><p>A further layer of contradiction comes from two additional studies. Teuwen et al. [<span>4</span>] used high-resolution epicardial mapping to compare conduction during sinus rhythm and atrial extrasystoles (AES) in over 160 patients; they found that decreases in conduction velocity and increases in delay occurred primarily in cases of aberrant wavefronts or breakthrough AES, but the degree of prematurity itself did not consistently correlate with increased conduction block or fractionation, indicating that not all PACs cause enhanced FAP burden [<span>4</span>]. Additionally, modeling and optical mapping work in canine atria by Roberts-Thomson et al. demonstrated that anisotropic conduction properties and resulting fractionated electrograms were highly dependent on tissue structural geometry and pacing rate rather than PAC direction per se—suggesting a more complex interplay than Toyama and Kumagai's direction-based hypothesis allows [<span>5</span>].</p><p>Taken together, these contradictory findings highlight that while Toyama and Kumagai's work provides valuable insight into how anisotropic conduction and extrastimuli may affect FAP distribution, other clinical and modeling data challenge the magnitude and regional specificity of those effects—emphasizing the need for standardized high-density mapping and controlled comparisons between spontaneous and paced PACs to resolve these discrepancies.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"42 1","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12750311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent Syncope in Patients With Reflex Syncope Treated With Dual-Chamber Pacemakers: Short-Term Associated Factors—A Single-Center Retrospective Study 双室起搏器治疗反射性晕厥患者复发性晕厥:短期相关因素-单中心回顾性研究
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-26 DOI: 10.1002/joa3.70257
Thai Duy Vo, Ngoc Dung Kieu, Le Uyen Phuong Tran, Cao Dat Tran, Tri Thuc Nguyen, Thi Thanh Binh Dao

Background

Dual-chamber pacemakers equipped with anti-reflex syncope algorithms are an established therapeutic option for preventing recurrent syncope in selected patients with reflex syncope. However, their efficacy in patients under 40 years old and in non-type 2B syncope remains uncertain and clinical predictors of recurrent syncope post-implantation are not well established.

Objective

To identify clinical factors associated with early recurrence of syncope in patients with reflex syncope who received dual-chamber pacemakers with anti-syncope functionality.

Methods

This retrospective cohort study included 117 patients (65% female) with reflex syncope confirmed by a positive tilt-table test. All received dual-chamber pacemakers. The primary endpoint was syncope recurrence within 6 months.

Results

Among 117 paced patients, 15 (12.8%) had recurrent syncope by 6 months. In the reduced Cox model, all three prespecified variables independently predicted recurrence: female sex (HR: 5.386; 95% CI: 1.689–17.175; p = 0.004), systolic blood pressure differential between the end of the passive phase and the syncope onset (HR: 1.036; 95% CI: 1.008–1.064; p = 0.011), number of prior syncope episodes (HR: 2.950; 95% CI: 1.565–5.561; p = 0.001). ROC-based cutoffs supported descriptive separation (e.g., ≥ 2.5 prior episodes; ΔSBP ≥ 87.5 mmHg; asystole ≥ 13.5 s), but continuous coding was used for modeling to avoid information loss.

Conclusion

Within 6 months of dual-chamber pacemaker implantation, recurrent syncope was more likely in female sex, a larger systolic blood pressure differential between the end of the passive phase and syncope onset, and greater pre-implantation syncope burdens.

背景:配备抗反射性晕厥算法的双室起搏器是预防选择性反射性晕厥患者复发性晕厥的既定治疗选择。然而,它们在40岁以下和非2B型晕厥患者中的疗效仍不确定,并且植入后复发晕厥的临床预测因素尚未很好地建立。目的:探讨反射性晕厥患者使用具有抗晕厥功能的双室起搏器后早期晕厥复发的相关临床因素。方法:本回顾性队列研究纳入117例经倾斜试验阳性证实的反射性晕厥患者(65%为女性)。所有患者都接受了双腔心脏起搏器。主要终点为6个月内晕厥复发。结果:117例患者中,15例(12.8%)在6个月后复发晕厥。在简化的Cox模型中,所有三个预先指定的变量都独立预测了复发:女性(HR: 5.386; 95% CI: 1.689-17.175; p = 0.004),被动期结束和晕厥发作之间的收缩压差(HR: 1.036; 95% CI: 1.008-1.064; p = 0.011),既往晕厥发作次数(HR: 2.950; 95% CI: 1.565-5.561; p = 0.001)。基于roc的截止值支持描述性分离(例如,≥2.5次既往发作;ΔSBP≥87.5 mmHg;心脏骤停≥13.5 s),但采用连续编码进行建模以避免信息丢失。结论:双腔起搏器植入6个月内,女性复发性晕厥的可能性更大,被动期结束与晕厥发作的收缩压差更大,植入前晕厥负担更大。
{"title":"Recurrent Syncope in Patients With Reflex Syncope Treated With Dual-Chamber Pacemakers: Short-Term Associated Factors—A Single-Center Retrospective Study","authors":"Thai Duy Vo,&nbsp;Ngoc Dung Kieu,&nbsp;Le Uyen Phuong Tran,&nbsp;Cao Dat Tran,&nbsp;Tri Thuc Nguyen,&nbsp;Thi Thanh Binh Dao","doi":"10.1002/joa3.70257","DOIUrl":"10.1002/joa3.70257","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dual-chamber pacemakers equipped with anti-reflex syncope algorithms are an established therapeutic option for preventing recurrent syncope in selected patients with reflex syncope. However, their efficacy in patients under 40 years old and in non-type 2B syncope remains uncertain and clinical predictors of recurrent syncope post-implantation are not well established.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To identify clinical factors associated with early recurrence of syncope in patients with reflex syncope who received dual-chamber pacemakers with anti-syncope functionality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included 117 patients (65% female) with reflex syncope confirmed by a positive tilt-table test. All received dual-chamber pacemakers. The primary endpoint was syncope recurrence within 6 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 117 paced patients, 15 (12.8%) had recurrent syncope by 6 months. In the reduced Cox model, all three prespecified variables independently predicted recurrence: female sex (HR: 5.386; 95% CI: 1.689–17.175; <i>p</i> = 0.004), systolic blood pressure differential between the end of the passive phase and the syncope onset (HR: 1.036; 95% CI: 1.008–1.064; <i>p</i> = 0.011), number of prior syncope episodes (HR: 2.950; 95% CI: 1.565–5.561; <i>p</i> = 0.001). ROC-based cutoffs supported descriptive separation (e.g., ≥ 2.5 prior episodes; ΔSBP ≥ 87.5 mmHg; asystole ≥ 13.5 s), but continuous coding was used for modeling to avoid information loss.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Within 6 months of dual-chamber pacemaker implantation, recurrent syncope was more likely in female sex, a larger systolic blood pressure differential between the end of the passive phase and syncope onset, and greater pre-implantation syncope burdens.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12742363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Undiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation 房颤导管消融患者保留射血分数的未诊断性心力衰竭。
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-26 DOI: 10.1002/joa3.70258
Masanaru Sawada, Ryuta Watanabe, Koichi Nagashima, Yuji Saito, Yuji Wakamatsu, Naoto Otsuka, Koichiro Hori, Shu Hirata, Moyuru Hirata, Yasuo Okumura

Background

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often coexist, but the prevalence of HFpEF among AF patients undergoing catheter ablation (CA) remains unclear.

Methods

We studied 127 AF patients with preserved ejection fraction (≥ 50%) undergoing initial CA. The Heart Failure Association Pre-test assessment, Echocardiography and natriuretic peptides, Functional testing, and Final etiology (HFA-PEFF) score was assessed 2 weeks before and 1 year after CA. Patients were grouped as low (0–1), intermediate (2–4), or high (5–6). The primary endpoint was AF freedom at 1 and 2 years; secondary endpoints were changes in HFA-PEFF score; tertiary endpoint was predictors of score improvement.

Results

Of 127 patients, 30 (23.6%) had HFpEF (score ≥ 5), 76 (59.8%) suspected (2–4), and 21 (16.5%) unlikely (≤ 1). Median follow-up 24.4[ 12.5–29.5] months. AF freedom at 1 year was high (86.4%, 91.7%, 89.7%; p = 0.66). Higher baseline score correlated with older age, female sex, hypertension, larger left atrial volume index (LAVI), elevated average E/e′, and increased left ventricular mass index. We divided patients into two groups: those with ≥ 1-point score improvement after CA (n = 89, 70.1%) and those whose score remained unchanged or worsened (n = 38, 29.9%). Improvement was associated with older age, larger LAVI, higher average E/e′, and elevated N-terminal pro-B-type natriuretic peptide. Multivariate analysis identified septal e' and LAVI as predictors. No patients had a score ≥ 5 at 1 year.

Conclusions

HFpEF or suspected HFpEF was common in AF CA candidates but not linked to recurrence. CA remarkably improved HFpEF features, suggesting reversibility.

背景:房颤(AF)和心力衰竭伴保留射血分数(HFpEF)经常共存,但在接受导管消融(CA)的房颤患者中HFpEF的患病率尚不清楚。方法:我们研究了127例接受初始CA的射血分数保留(≥50%)的房颤患者。在CA前2周和CA后1年评估心力衰竭相关性试验前评估、超声心动图和利钠肽、功能测试和最终病因学(HFA-PEFF)评分。患者分为低(0-1)、中(2-4)和高(5-6)。主要终点是1年和2年的房颤自由度;次要终点为HFA-PEFF评分的变化;第三终点是评分改善的预测指标。结果:127例患者中,30例(23.6%)为HFpEF(评分≥5),76例(59.8%)为疑似(2-4),21例(16.5%)为不可能(≤1)。中位随访24.4[12.5-29.5]个月。1年房颤自由度较高(86.4%,91.7%,89.7%;p = 0.66)。基线评分较高与年龄较大、女性、高血压、左房容积指数(LAVI)较大、平均E/ E′升高、左室质量指数升高相关。我们将患者分为两组:CA后评分改善≥1分的患者(n = 89, 70.1%)和评分保持不变或恶化的患者(n = 38, 29.9%)。改善与年龄较大、LAVI较大、平均E/ E′较高以及n端前b型利钠肽升高有关。多变量分析确定间隔e′和LAVI为预测因子。1年时,没有患者的评分≥5。结论:HFpEF或疑似HFpEF在AF CA患者中很常见,但与复发无关。CA显著改善了HFpEF特征,提示可逆性。
{"title":"Undiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation","authors":"Masanaru Sawada,&nbsp;Ryuta Watanabe,&nbsp;Koichi Nagashima,&nbsp;Yuji Saito,&nbsp;Yuji Wakamatsu,&nbsp;Naoto Otsuka,&nbsp;Koichiro Hori,&nbsp;Shu Hirata,&nbsp;Moyuru Hirata,&nbsp;Yasuo Okumura","doi":"10.1002/joa3.70258","DOIUrl":"10.1002/joa3.70258","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often coexist, but the prevalence of HFpEF among AF patients undergoing catheter ablation (CA) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We studied 127 AF patients with preserved ejection fraction (≥ 50%) undergoing initial CA. The Heart Failure Association Pre-test assessment, Echocardiography and natriuretic peptides, Functional testing, and Final etiology (HFA-PEFF) score was assessed 2 weeks before and 1 year after CA. Patients were grouped as low (0–1), intermediate (2–4), or high (5–6). The primary endpoint was AF freedom at 1 and 2 years; secondary endpoints were changes in HFA-PEFF score; tertiary endpoint was predictors of score improvement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 127 patients, 30 (23.6%) had HFpEF (score ≥ 5), 76 (59.8%) suspected (2–4), and 21 (16.5%) unlikely (≤ 1). Median follow-up 24.4[ 12.5–29.5] months. AF freedom at 1 year was high (86.4%, 91.7%, 89.7%; <i>p</i> = 0.66). Higher baseline score correlated with older age, female sex, hypertension, larger left atrial volume index (LAVI), elevated average <i>E</i>/<i>e</i>′, and increased left ventricular mass index. We divided patients into two groups: those with ≥ 1-point score improvement after CA (<i>n</i> = 89, 70.1%) and those whose score remained unchanged or worsened (<i>n</i> = 38, 29.9%). Improvement was associated with older age, larger LAVI, higher average <i>E</i>/<i>e</i>′, and elevated N-terminal pro-B-type natriuretic peptide. Multivariate analysis identified septal e' and LAVI as predictors. No patients had a score ≥ 5 at 1 year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HFpEF or suspected HFpEF was common in AF CA candidates but not linked to recurrence. CA remarkably improved HFpEF features, suggesting reversibility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12742364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated Meta-Analysis of Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Preserved Ejection Fraction 保留射血分数的心房颤动合并心力衰竭患者导管消融与药物治疗的最新meta分析
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-19 DOI: 10.1002/joa3.70236
Shariq Ahmed Wani, Muhammad Abdullah Naveed, Anzel Saeed, Ahila Ali, Bazil Azeem, Talha Ali, Hamza Naveed, Muhammad Zia Khan, Nosheen Pervaiz, Binish Qureshi, Muhammad Bilal Munir, Sivaram Neppala

Background

The advantage of catheter ablation compared to medical therapy for atrial fibrillation (AF) in patients diagnosed with heart failure with preserved ejection fraction (HFpEF) remains indeterminate. A meta-analysis was conducted to assess outcomes within this population.

Methods

We searched MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov through May 2025. Twelve studies satisfied the inclusion criteria, encompassing a total sample size of 43 584 individuals. Outcomes included primary composite endpoints, HF hospitalizations, all-cause mortality, AF recurrence, cardiovascular (CV) mortality, all-cause hospitalization, and stroke. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models; heterogeneity was assessed using I2 statistics. Publication bias and sensitivity analyses were also performed.

Results

Catheter ablation notably reduced the primary composite endpoint (HR, 0.53; 95% CI, 0.41–0.68; p < 0.01) and hospitalizations due to heart failure (HR, 0.62; 95% CI, 0.48–0.81; p < 0.01). The overall mortality rate was reduced with ablation (HR, 0.64; 95% CI, 0.45–0.91; p < 0.01). A trend toward lower atrial fibrillation recurrence was observed (HR 0.64; 95% CI 0.38–1.10). The intervention significantly decreased the risk of stroke (HR, 0.66; 95% CI, 0.60–0.72; p < 0.01). Other outcomes indicated a favorable effect of ablation; however, they did not attain statistical significance.

Conclusion

In patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), catheter ablation is correlated with substantially enhanced outcomes compared to medical therapy, particularly in decreasing composite events, mortality, and the incidence of stroke.

Trial Registration

PROSPERO (CRD420251069889)

背景:对于诊断为心力衰竭并保留射血分数(HFpEF)的心房颤动(AF)患者,导管消融与药物治疗相比的优势仍不确定。进行了一项荟萃分析来评估该人群的结果。方法:我们检索MEDLINE、Embase、Cochrane CENTRAL和ClinicalTrials.gov至2025年5月。12项研究符合纳入标准,总样本量为43 584人。结果包括主要复合终点、心衰住院、全因死亡率、房颤复发、心血管(CV)死亡率、全因住院和卒中。采用随机效应模型计算合并风险比(hr)和95%置信区间(ci);采用i2统计量评估异质性。还进行了发表偏倚和敏感性分析。结果:导管消融显著降低了主要复合终点(HR, 0.53; 95% CI, 0.41-0.68; p p p p)结论:与药物治疗相比,房颤(AF)和心力衰竭保留射血分数(HFpEF)患者的导管消融与显著增强的结局相关,特别是在降低复合事件、死亡率和卒中发生率方面。试验注册:PROSPERO (CRD420251069889)。
{"title":"Updated Meta-Analysis of Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Preserved Ejection Fraction","authors":"Shariq Ahmed Wani,&nbsp;Muhammad Abdullah Naveed,&nbsp;Anzel Saeed,&nbsp;Ahila Ali,&nbsp;Bazil Azeem,&nbsp;Talha Ali,&nbsp;Hamza Naveed,&nbsp;Muhammad Zia Khan,&nbsp;Nosheen Pervaiz,&nbsp;Binish Qureshi,&nbsp;Muhammad Bilal Munir,&nbsp;Sivaram Neppala","doi":"10.1002/joa3.70236","DOIUrl":"10.1002/joa3.70236","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The advantage of catheter ablation compared to medical therapy for atrial fibrillation (AF) in patients diagnosed with heart failure with preserved ejection fraction (HFpEF) remains indeterminate. A meta-analysis was conducted to assess outcomes within this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov through May 2025. Twelve studies satisfied the inclusion criteria, encompassing a total sample size of 43 584 individuals. Outcomes included primary composite endpoints, HF hospitalizations, all-cause mortality, AF recurrence, cardiovascular (CV) mortality, all-cause hospitalization, and stroke. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models; heterogeneity was assessed using <i>I</i><sup>2</sup> statistics. Publication bias and sensitivity analyses were also performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Catheter ablation notably reduced the primary composite endpoint (HR, 0.53; 95% CI, 0.41–0.68; <i>p</i> &lt; 0.01) and hospitalizations due to heart failure (HR, 0.62; 95% CI, 0.48–0.81; <i>p</i> &lt; 0.01). The overall mortality rate was reduced with ablation (HR, 0.64; 95% CI, 0.45–0.91; <i>p</i> &lt; 0.01). A trend toward lower atrial fibrillation recurrence was observed (HR 0.64; 95% CI 0.38–1.10). The intervention significantly decreased the risk of stroke (HR, 0.66; 95% CI, 0.60–0.72; <i>p</i> &lt; 0.01). Other outcomes indicated a favorable effect of ablation; however, they did not attain statistical significance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), catheter ablation is correlated with substantially enhanced outcomes compared to medical therapy, particularly in decreasing composite events, mortality, and the incidence of stroke.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>PROSPERO (CRD420251069889)</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12715588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activation Map-Guided Ablation for Persistent Atrial Fibrillation Using Rhythmia Mapping System 心律定位系统激活图引导持续性心房颤动消融。
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-17 DOI: 10.1002/joa3.70256
Yosuke Murase, Yasuya Inden, Yasuhiro Ogawa, Hajime Imai, Naoaki Kano, Keita Mamiya, Katsuhiro Kawaguchi, Toyoaki Murohara

Background

Creating activation map during atrial fibrillation (AF) has been challenging.

Methods

Activation map-guided ablation was performed in 29 persistent AF patients using the Rhythmia mapping system.

Results

After activation map-guided AF ablation, patients with left atrial volume (LAV) < 96.5 mL and ratio of organized atrial electrogram pattern (ROAE) ≥ 40% had significantly higher atrial arrhythmia-free rates than other patients (84% vs. 20%, log-rank test; p < 0.001).

Conclusions

The patients with smaller LA and highly organized atrial electrogram pattern had significantly lower atrial arrhythmia recurrence rate after activation map-guided AF ablation.

背景:建立心房颤动(AF)期间的激活图一直具有挑战性。方法:应用心律失常测图系统对29例持续性房颤患者进行激活图引导消融。结果:激活图引导AF消融后,左房容积(LAV) p < 0.05。结论:激活图引导AF消融后,左房容积较小且心房电图高度有序的患者心房心律失常复发率明显降低。
{"title":"Activation Map-Guided Ablation for Persistent Atrial Fibrillation Using Rhythmia Mapping System","authors":"Yosuke Murase,&nbsp;Yasuya Inden,&nbsp;Yasuhiro Ogawa,&nbsp;Hajime Imai,&nbsp;Naoaki Kano,&nbsp;Keita Mamiya,&nbsp;Katsuhiro Kawaguchi,&nbsp;Toyoaki Murohara","doi":"10.1002/joa3.70256","DOIUrl":"10.1002/joa3.70256","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Creating activation map during atrial fibrillation (AF) has been challenging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Activation map-guided ablation was performed in 29 persistent AF patients using the Rhythmia mapping system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After activation map-guided AF ablation, patients with left atrial volume (LAV) &lt; 96.5 mL and ratio of organized atrial electrogram pattern (ROAE) ≥ 40% had significantly higher atrial arrhythmia-free rates than other patients (84% vs. 20%, log-rank test; <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The patients with smaller LA and highly organized atrial electrogram pattern had significantly lower atrial arrhythmia recurrence rate after activation map-guided AF ablation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Sacubitril/Valsartan Among Heart Failure Individuals With Implanted Cardiac Defibrillators: A Systematic Review and Meta-Analysis 沙比里尔/缬沙坦对植入心脏除颤器的心力衰竭患者的疗效:系统回顾和荟萃分析
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-15 DOI: 10.1002/joa3.70247
Hila Asham, Shaghayegh Salehian, Afshin Gharekhani, Naser Safaei, Parvin Sarbakhsh, Taher Entezari-Maleki

Introduction

Antiarrhythmic effects of sacubitril/valsartan in heart failure (HF) have been previously reported; however, its impact among individuals with ventricular arrhythmias with cardiac defibrillators remains unclear. Therefore, we performed this systematic review and meta-analysis to address this lack of evidence.

Method

A systematic search of PubMed, Embase, and Cochrane Library was conducted from inception until February 26, 2025. Binary and continuous variables were analyzed by odds ratio (OR) and mean differences, respectively. All analyses were performed using a random-effects model by RevMan.

Results

Four paired observational cohort studies, including 397 patients with HF and implanted cardiac defibrillators (ICDs) were enrolled. This study showed that sacubitril/valsartan could significantly reduce the incidence of ICD shocks (OR, 0.33; 95% CI, 0.19 to 0.60; p = 0.0003; I2 = 13%), appropriate ICD shocks (OR, 0.21; 95% CI, 0.10 to 0.47; p = 0.0001; I2 = 0%), NSVT duration (OR, −1.86; 95% CI, −3.43 to −0.30; p = 0.02; I2 = 86%), and biventricular (Biv) pacing < 90% (OR, 0.15; 95% CI, 0.03 to 0.83; p = 0.03; I2 = 0%). However, the mata-analysis didn't reveal a significant association between sacubitril/valsartan and a lower rate of ventricular arrhythmia, sustained ventricular tachycardia (SVT), non-sustained ventricular tachycardia (NSVT), inappropriate ICD shocks, premature ventricular contractions per hour (PVC/h), and left ventricular ejection fraction (LVEF).

Conclusion

Sacubitril/valsartan may have a potential benefit among HF patients with cardiac defibrillators; future investigations are warranted to confirm the antiarrhythmic effects of sacubitril/valsartan in this setting.

引言:既往有报道称苏比里尔/缬沙坦对心力衰竭(HF)的抗心律失常作用;然而,它对使用心脏除颤器的室性心律失常患者的影响尚不清楚。因此,我们进行了这项系统综述和荟萃分析来解决这一缺乏证据的问题。方法:系统检索PubMed、Embase和Cochrane图书馆,检索时间为2025年2月26日。二元变量和连续变量分别采用优势比(OR)和平均差异进行分析。所有分析均采用RevMan的随机效应模型进行。结果:纳入了4项成对观察队列研究,包括397例HF患者和植入式心脏除颤器(ICDs)。本研究显示,沙比利/缬沙坦可显著降低ICD冲击发生率(OR, 0.33; 95% CI, 0.19 ~ 0.60; p = 0.0003; I2 = 13%)、适当的ICD冲击发生率(OR, 0.21; 95% CI, 0.10 ~ 0.47; p = 0.0001; I2 = 0%)、非svt持续时间(OR, -1.86; 95% CI, -3.43 ~ -0.30; p = 0.02; I2 = 86%)和双室起搏p = 0.03;i2 = 0%)。然而,数据分析并未显示苏比利/缬沙坦与较低的室性心律失常、持续性室性心动过速(SVT)、非持续性室性心动过速(NSVT)、不适当的ICD电击、每小时室性早搏(PVC/h)和左室射血分数(LVEF)发生率之间存在显著关联。结论:Sacubitril/缬沙坦可能对使用心脏除颤器的HF患者有潜在的益处;在这种情况下,有必要进行进一步的研究来证实苏比里尔/缬沙坦的抗心律失常作用。
{"title":"Efficacy of Sacubitril/Valsartan Among Heart Failure Individuals With Implanted Cardiac Defibrillators: A Systematic Review and Meta-Analysis","authors":"Hila Asham,&nbsp;Shaghayegh Salehian,&nbsp;Afshin Gharekhani,&nbsp;Naser Safaei,&nbsp;Parvin Sarbakhsh,&nbsp;Taher Entezari-Maleki","doi":"10.1002/joa3.70247","DOIUrl":"10.1002/joa3.70247","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Antiarrhythmic effects of sacubitril/valsartan in heart failure (HF) have been previously reported; however, its impact among individuals with ventricular arrhythmias with cardiac defibrillators remains unclear. Therefore, we performed this systematic review and meta-analysis to address this lack of evidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A systematic search of PubMed, Embase, and Cochrane Library was conducted from inception until February 26, 2025. Binary and continuous variables were analyzed by odds ratio (OR) and mean differences, respectively. All analyses were performed using a random-effects model by RevMan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four paired observational cohort studies, including 397 patients with HF and implanted cardiac defibrillators (ICDs) were enrolled. This study showed that sacubitril/valsartan could significantly reduce the incidence of ICD shocks (OR, 0.33; 95% CI, 0.19 to 0.60; <i>p</i> = 0.0003; <i>I</i><sup>2</sup> = 13%), appropriate ICD shocks (OR, 0.21; 95% CI, 0.10 to 0.47; <i>p</i> = 0.0001; <i>I</i><sup>2</sup> = 0%), NSVT duration (OR, −1.86; 95% CI, −3.43 to −0.30; <i>p</i> = 0.02; <i>I<sup>2</sup></i> = 86%), and biventricular (Biv) pacing &lt; 90% (OR, 0.15; 95% CI, 0.03 to 0.83; <i>p</i> = 0.03; <i>I</i><sup>2</sup> = 0%). However, the mata-analysis didn't reveal a significant association between sacubitril/valsartan and a lower rate of ventricular arrhythmia, sustained ventricular tachycardia (SVT), non-sustained ventricular tachycardia (NSVT), inappropriate ICD shocks, premature ventricular contractions per hour (PVC/h), and left ventricular ejection fraction (LVEF).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Sacubitril/valsartan may have a potential benefit among HF patients with cardiac defibrillators; future investigations are warranted to confirm the antiarrhythmic effects of sacubitril/valsartan in this setting.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias 胰高血糖素样肽-1受体激动剂与心律失常风险的关系
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-15 DOI: 10.1002/joa3.70242
Vikash Jaiswal, Muhammad Hanif, Aman Goyal, Juveriya Yasmeen, Vamsi Garimella, Yusra Mashkoor, Roopeessh Vempati, Novonil Deb, Yusra Minahil Nasir, Kripa Rajak, Abhigan Babu Shrestha, Jishanth Mattumpuram, Andrew Weinberg

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity-related cardiovascular risks. However, their effect on arrhythmias is not well established with limited literature.

Objective

This study aimed to assess the efficacy of GLP-1 RAs and the risk of cardiac arrest and arrhythmias in obese patients based on real-world evidence.

Methods

The TriNetX Global Collaborative Network research database was used to identify obese patients aged ≥ 18 years from January 2020 to December 2022. Patients were categorized into two groups, one with GLP-1 RAs and a control group without GLP-1 RAs. After propensity score matching (PSM), relative risk (RR) was used to compare outcomes over follow-up periods of 1 year and 3 years.

Results

After 1:1 PSM, the study cohort comprised 342 753 patients in both groups. The study population had a mean age of 56.35 years. PSM analysis at 1 year follow-up showed that the GLP-1 RAs group of patients had a significantly lower risk of cardiac arrest (RR, 0.33 (95% CI: 0.31–0.37), p < 0.01), atrial fibrillation/flutter (RR, 0.63 (95% CI: 0.60–0.66), p < 0.01), ventricular fibrillation (RR, 0.45 (95% CI: 0.38–0.53), p < 0.01), ventricular tachycardia (RR, 0.56 (95% CI: 0.52–0.60), p < 0.01), second-degree atrioventricular (AV) block (RR, 0.72 (95% CI: 0.63–0.82), p < 0.01), and complete heart block (RR, 0.62 (95% CI: 0.55–0.70), p < 0.01) when compared with the control group. Similar trends were observed for the 3-year follow-up as well.

Conclusion

This study suggests that GLP-1 RAs use among obese patients was associated with lower risk of arrhythmias at both 1-year and 3-year follow-ups.

背景:胰高血糖素样肽-1受体激动剂(GLP-1 RAs)最初被设计用于治疗糖尿病(DM),已被证明具有减轻肥胖相关心血管风险的潜力。然而,由于文献有限,它们对心律失常的影响尚未得到很好的证实。目的:本研究旨在基于真实证据评估GLP-1 RAs的疗效和肥胖患者心脏骤停和心律失常的风险。方法:使用TriNetX全球协作网络研究数据库,对2020年1月至2022年12月年龄≥18岁的肥胖患者进行识别。患者分为两组,一组有GLP-1 RAs,另一组没有GLP-1 RAs。在倾向评分匹配(PSM)后,使用相对风险(RR)比较随访1年和3年的结果。结果:1:1 PSM后,两组共342753例患者。研究人群的平均年龄为56.35岁。随访1年的PSM分析显示,GLP-1 RAs组患者发生心脏骤停的风险显著降低(RR, 0.33 (95% CI: 0.31-0.37), p p p p p p p p p p结论:本研究提示肥胖患者在随访1年和3年时,GLP-1 RAs的使用与心律失常的风险降低相关。
{"title":"Association Between Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias","authors":"Vikash Jaiswal,&nbsp;Muhammad Hanif,&nbsp;Aman Goyal,&nbsp;Juveriya Yasmeen,&nbsp;Vamsi Garimella,&nbsp;Yusra Mashkoor,&nbsp;Roopeessh Vempati,&nbsp;Novonil Deb,&nbsp;Yusra Minahil Nasir,&nbsp;Kripa Rajak,&nbsp;Abhigan Babu Shrestha,&nbsp;Jishanth Mattumpuram,&nbsp;Andrew Weinberg","doi":"10.1002/joa3.70242","DOIUrl":"10.1002/joa3.70242","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity-related cardiovascular risks. However, their effect on arrhythmias is not well established with limited literature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to assess the efficacy of GLP-1 RAs and the risk of cardiac arrest and arrhythmias in obese patients based on real-world evidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The TriNetX Global Collaborative Network research database was used to identify obese patients aged ≥ 18 years from January 2020 to December 2022. Patients were categorized into two groups, one with GLP-1 RAs and a control group without GLP-1 RAs. After propensity score matching (PSM), relative risk (RR) was used to compare outcomes over follow-up periods of 1 year and 3 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After 1:1 PSM, the study cohort comprised 342 753 patients in both groups. The study population had a mean age of 56.35 years. PSM analysis at 1 year follow-up showed that the GLP-1 RAs group of patients had a significantly lower risk of cardiac arrest (RR, 0.33 (95% CI: 0.31–0.37), <i>p</i> &lt; 0.01), atrial fibrillation/flutter (RR, 0.63 (95% CI: 0.60–0.66), <i>p</i> &lt; 0.01), ventricular fibrillation (RR, 0.45 (95% CI: 0.38–0.53), <i>p</i> &lt; 0.01), ventricular tachycardia (RR, 0.56 (95% CI: 0.52–0.60), <i>p</i> &lt; 0.01), second-degree atrioventricular (AV) block (RR, 0.72 (95% CI: 0.63–0.82), <i>p</i> &lt; 0.01), and complete heart block (RR, 0.62 (95% CI: 0.55–0.70), <i>p</i> &lt; 0.01) when compared with the control group. Similar trends were observed for the 3-year follow-up as well.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study suggests that GLP-1 RAs use among obese patients was associated with lower risk of arrhythmias at both 1-year and 3-year follow-ups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12704023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Hurdles, Not Cardiologist Awareness: The Barriers to CPET Availability in Japan 系统障碍,而不是心脏病专家的意识:日本CPET可用性的障碍
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-11 DOI: 10.1002/joa3.70251
Takahiro Kamihara, Takuya Omura, Atsuya Shimizu
<p>We read with great interest the article “Factors Influencing the Availability of Cardiopulmonary Exercise Testing for Patients Undergoing Cardiac Resynchronization Therapy in Japan,” which appeared in your esteemed journal [<span>1</span>]. The paper provides valuable data by revealing the remarkably low rate of cardiopulmonary exercise testing (CPET) among patients who have undergone cardiac resynchronization therapy (CRT) implantation in Japan. This finding is crucial as it highlights the current status and challenges of CPET dissemination in Japanese healthcare. However, we believe that the interpretation and conclusions of this study overlook some fundamental issues within Japan's medical infrastructure and contain several logical inconsistencies that warrant discussion.</p><p>The first point is the logical inconsistency between infrastructure and awareness. The “Discussion” section of the article accurately points out a structural problem: only 21% of medical facilities in Japan are equipped with CPET devices. Despite this, the “Conclusion” proposes that emphasizing the “importance of CPET” is the primary solution to improve its implementation rate. This represents a logical leap, as it ignores the fundamental issue of a lack of necessary equipment and instead reduces the problem to one of physician awareness. The implementation rate cannot be substantially improved without the necessary infrastructure, regardless of how much its importance is emphasized. Similar to the regional disparities observed in catheter ablation, which is more widely adopted than CRT, the lack of infrastructure is a key factor [<span>2</span>]. It is highly probable that in facilities with the equipment, medical professionals are already actively performing CPET for their patients, but their capacity is limited. Conversely, in facilities without the equipment, healthcare providers cannot perform CPET even if they understand its importance. The conclusion of this study risks sending an incorrect message to the medical community—that the low CPET adoption rate is due to a lack of effort from practitioners, rather than a systemic issue. This is a claim made without sufficient scientific evidence.</p><p>Furthermore, we note the limits of DPC data and the over-generalization of conclusions. The authors themselves acknowledge a limitation: the Diagnosis Procedure Combination system (DPC) dataset used in the study only covers a fraction of all hospitals in Japan. Yet, they generalize the conclusion that “the CPET implementation rate is only 3%” to represent the entire country. Many hospitals operating on a fee-for-service basis are not included in the DPC dataset [<span>3</span>]. These hospitals have a financial incentive to perform more tests and procedures, and thus may be more actively conducting CPET than their DPC-participating counterparts. Therefore, the data presented in this study merely reflect the reality within DPC. To extrapolate these findings to the entir
我们非常感兴趣地阅读了您尊敬的期刊[1]上发表的文章“影响日本心脏再同步化治疗患者心肺运动测试可用性的因素”。本研究揭示了日本心脏再同步化治疗(CRT)植入术患者的心肺运动测试(CPET)率非常低,提供了有价值的数据。这一发现是至关重要的,因为它突出了CPET在日本医疗保健传播的现状和挑战。然而,我们认为,这项研究的解释和结论忽略了日本医疗基础设施中的一些基本问题,并包含一些值得讨论的逻辑不一致。第一点是基础设施和意识之间的逻辑不一致。文章的“讨论”部分准确地指出了一个结构性问题:日本只有21%的医疗机构配备了CPET设备。尽管如此,“结论”提出强调“CPET的重要性”是提高其执行率的首要解决方案。这是一个逻辑上的飞跃,因为它忽略了缺乏必要设备的根本问题,而把问题归结为医生意识的问题。如果没有必要的基础设施,无论多么强调其重要性,执行率都不可能大幅度提高。导管消融的应用比CRT更为广泛,与此类似,缺乏基础设施也是一个关键因素。很有可能,在有设备的设施中,医疗专业人员已经在积极地为患者进行CPET,但他们的能力有限。相反,在没有设备的设施中,即使医疗保健提供者了解CPET的重要性,他们也无法执行CPET。这项研究的结论可能会向医学界传递一个错误的信息,即低CPET采用率是由于从业者缺乏努力,而不是一个系统性问题。这是一种没有充分科学证据的说法。此外,我们注意到DPC数据的局限性和结论的过度概括。作者自己也承认存在局限性:研究中使用的诊断程序组合系统(DPC)数据集仅覆盖了日本所有医院的一小部分。然而,他们将“CPET执行率仅为3%”的结论概括为代表全国。许多按服务收费的医院不包括在DPC数据集[3]中。这些医院有进行更多测试和程序的经济动机,因此可能比参与dpc的同行更积极地开展CPET。因此,本研究的数据仅仅反映了DPC内部的真实情况。将这些发现外推到整个国家是一种逻辑上的矛盾,它忽视了数据来源的固有局限性。最后,老年患者的CPET安全性和实施率之间存在差异。“讨论”部分引用了先前的研究,证实了CPET在老年患者中的安全性,表明年龄不应成为其使用的障碍。然而,“结果”部分显示,非cpet组明显年龄较大,“结论”将70岁以上的年龄确定为影响不执行的因素。这种矛盾——尽管年龄被证明是安全的,但它是一个障碍——是文章论点的主要弱点。造成这种差异的真正原因可能不是医务人员意识的简单问题,而是DPC数据没有捕捉到的更细微的临床因素,如虚弱或急性、不稳定的状况。总之,我们认为提高CPET的执行率需要的不仅仅是宣传活动。它要求采取更根本的办法,解决区域医疗设施缺乏设备和人力资源的问题。作者没有什么可报告的。这项研究中没有人类参与者。作者没有什么可报告的。作者没有什么可报告的。作者声明无利益冲突。在这封信中,没有进行数据分析。
{"title":"Systemic Hurdles, Not Cardiologist Awareness: The Barriers to CPET Availability in Japan","authors":"Takahiro Kamihara,&nbsp;Takuya Omura,&nbsp;Atsuya Shimizu","doi":"10.1002/joa3.70251","DOIUrl":"https://doi.org/10.1002/joa3.70251","url":null,"abstract":"&lt;p&gt;We read with great interest the article “Factors Influencing the Availability of Cardiopulmonary Exercise Testing for Patients Undergoing Cardiac Resynchronization Therapy in Japan,” which appeared in your esteemed journal [&lt;span&gt;1&lt;/span&gt;]. The paper provides valuable data by revealing the remarkably low rate of cardiopulmonary exercise testing (CPET) among patients who have undergone cardiac resynchronization therapy (CRT) implantation in Japan. This finding is crucial as it highlights the current status and challenges of CPET dissemination in Japanese healthcare. However, we believe that the interpretation and conclusions of this study overlook some fundamental issues within Japan's medical infrastructure and contain several logical inconsistencies that warrant discussion.&lt;/p&gt;&lt;p&gt;The first point is the logical inconsistency between infrastructure and awareness. The “Discussion” section of the article accurately points out a structural problem: only 21% of medical facilities in Japan are equipped with CPET devices. Despite this, the “Conclusion” proposes that emphasizing the “importance of CPET” is the primary solution to improve its implementation rate. This represents a logical leap, as it ignores the fundamental issue of a lack of necessary equipment and instead reduces the problem to one of physician awareness. The implementation rate cannot be substantially improved without the necessary infrastructure, regardless of how much its importance is emphasized. Similar to the regional disparities observed in catheter ablation, which is more widely adopted than CRT, the lack of infrastructure is a key factor [&lt;span&gt;2&lt;/span&gt;]. It is highly probable that in facilities with the equipment, medical professionals are already actively performing CPET for their patients, but their capacity is limited. Conversely, in facilities without the equipment, healthcare providers cannot perform CPET even if they understand its importance. The conclusion of this study risks sending an incorrect message to the medical community—that the low CPET adoption rate is due to a lack of effort from practitioners, rather than a systemic issue. This is a claim made without sufficient scientific evidence.&lt;/p&gt;&lt;p&gt;Furthermore, we note the limits of DPC data and the over-generalization of conclusions. The authors themselves acknowledge a limitation: the Diagnosis Procedure Combination system (DPC) dataset used in the study only covers a fraction of all hospitals in Japan. Yet, they generalize the conclusion that “the CPET implementation rate is only 3%” to represent the entire country. Many hospitals operating on a fee-for-service basis are not included in the DPC dataset [&lt;span&gt;3&lt;/span&gt;]. These hospitals have a financial incentive to perform more tests and procedures, and thus may be more actively conducting CPET than their DPC-participating counterparts. Therefore, the data presented in this study merely reflect the reality within DPC. To extrapolate these findings to the entir","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.70251","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Catheter Knotting in Pulse-Select Pulsed Field Ablation: Mechanisms and a Practical Strategy for Resolution 处理脉冲选择脉冲场消融中的导管打结:解决的机制和实用策略
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-11 DOI: 10.1002/joa3.70250
Masateru Takigawa, Ryosuke Kato, Masaki Honda, Iwanari Kawamura, Ryo Tateishi, Miho Negishi, Kentaro Goto, Takuro Nishimura, Kazuya Yamao, Susumu Tao, Shinsuke Miyazaki, Tetsuo Sasano

Background

Pulsed field ablation (PFA) using the PulseSelect catheter is effective for atrial fibrillation but may occasionally result in catheter deformation or knotting.

Methods

We analyzed 25 PulseSelect catheters used for AF ablation to identify knotting mechanisms. Two reproducible knot types were observed. A resolution strategy was tested: retraction to the sheath tip, wire withdrawal, and gradual advancement with or without rotation.

Results

The knot was resolved in 24 catheters (96%), with 21 (84%) resolved on the first attempt. One severe type 1 knot was resistant but safely removed.

Conclusions

A structured, non-forceful approach utilizing the catheter's elasticity effectively resolves knotting without rendering the catheter unusable.

脉冲场消融(PFA)使用脉冲选择导管是有效的房颤,但偶尔可能导致导管变形或打结。方法分析25根用于房颤消融的脉冲选择导管的打结机制。观察到两种可重复的结型。测试了一种解决策略:收缩到护套尖端,钢丝拔出,在旋转或不旋转的情况下逐渐推进。结果24根(96%)导管结解决,其中21根(84%)首次解决。一个严重的1型结有抵抗性,但被安全移除。结论:利用导管的弹性,采用结构化、非强制的方法有效地解决了打结问题,而不会使导管无法使用。
{"title":"Managing Catheter Knotting in Pulse-Select Pulsed Field Ablation: Mechanisms and a Practical Strategy for Resolution","authors":"Masateru Takigawa,&nbsp;Ryosuke Kato,&nbsp;Masaki Honda,&nbsp;Iwanari Kawamura,&nbsp;Ryo Tateishi,&nbsp;Miho Negishi,&nbsp;Kentaro Goto,&nbsp;Takuro Nishimura,&nbsp;Kazuya Yamao,&nbsp;Susumu Tao,&nbsp;Shinsuke Miyazaki,&nbsp;Tetsuo Sasano","doi":"10.1002/joa3.70250","DOIUrl":"https://doi.org/10.1002/joa3.70250","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pulsed field ablation (PFA) using the PulseSelect catheter is effective for atrial fibrillation but may occasionally result in catheter deformation or knotting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed 25 PulseSelect catheters used for AF ablation to identify knotting mechanisms. Two reproducible knot types were observed. A resolution strategy was tested: retraction to the sheath tip, wire withdrawal, and gradual advancement with or without rotation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The knot was resolved in 24 catheters (96%), with 21 (84%) resolved on the first attempt. One severe type 1 knot was resistant but safely removed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A structured, non-forceful approach utilizing the catheter's elasticity effectively resolves knotting without rendering the catheter unusable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.70250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145750802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced Left Atrial Appendage Flow Velocity as a Risk of Thromboembolic Events After Catheter Ablation of Atrial Fibrillation 房颤导管消融后左心耳血流速度降低对血栓栓塞事件的影响
IF 1.7 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-12-10 DOI: 10.1002/joa3.70233
Shintaro Yamagami, Satoshi Shizuta, Munekazu Tanaka, Shushi Nishiwaki, Takanori Aizawa, Akihiro Komasa, Takashi Yoshizawa, Tetsuma Kawaji, Chihiro Ota, Naoaki Onishi, Yasuhiro Sasaki, Mitsuhiko Yahata, Kentaro Nakai, Mamoru Hayano, Tetsushi Nakao, Koji Hanazawa, Koji Goto, Takahiro Doi, Toshihiro Tamura, Koh Ono, Takeshi Kimura

Background

Reduced left atrial appendage flow velocity (LAAFV) on transesophageal echocardiography (TEE) is recognized as a predictor of thromboembolic events (TEs) in patients with atrial fibrillation (AF). However, its long-term prognostic value following AF ablation remains unclear.

Methods and Results

We retrospectively evaluated 1521 patients undergoing AF ablation who underwent preprocedural TEE. Patients were categorized into two groups based on LAAFV: reduced (≤ 21.4 cm/s, n = 99) and preserved (> 21.4 cm/s, n = 1422). The primary outcome was TEs. Secondary outcomes included arrhythmia recurrence and major adverse cardiovascular events (MACEs), defined as a composite of all-cause death, stroke, major bleeding, and heart failure hospitalization, as well as individual components and cardiovascular mortality. Over a mean follow-up of 49 ± 32 months, TEs occurred in 19 patients (1.2%). The 5-year cumulative incidence of TEs was significantly higher in the reduced LAAFV group (6.7% vs. 0.9%, p < 0.0001), despite a lower rate of anticoagulation discontinuation (20.1% vs. 57.1%, p < 0.0001). Multivariable analysis identified reduced LAAFV as an independent predictor of TEs. It was also associated with higher risks for all secondary endpoints.

Conclusions

Reduced preprocedural LAAFV is associated with adverse long-term clinical outcomes after AF ablation, including a significantly increased risk of thromboembolic events.

经食管超声心动图(TEE)左心耳血流速度(LAAFV)降低被认为是心房颤动(AF)患者血栓栓塞事件(TEs)的预测因子。然而,其在房颤消融后的长期预后价值尚不清楚。方法与结果回顾性评价1521例房颤消融术前TEE患者。根据LAAFV分为降低组(≤21.4 cm/s, n = 99)和保留组(≤21.4 cm/s, n = 1422)。主要结局为TEs。次要结局包括心律失常复发和主要心血管不良事件(mace),定义为全因死亡、中风、大出血和心力衰竭住院的复合,以及个体成分和心血管死亡率。在平均49±32个月的随访中,有19例(1.2%)患者发生TEs。LAAFV降低组的5年累计TEs发生率显著高于对照组(6.7% vs. 0.9%, p < 0.0001),尽管抗凝停药率较低(20.1% vs. 57.1%, p < 0.0001)。多变量分析发现LAAFV降低是TEs的独立预测因子。它还与所有次要终点的高风险相关。结论:术前LAAFV降低与房颤消融后不良的长期临床结果相关,包括血栓栓塞事件的风险显著增加。
{"title":"Reduced Left Atrial Appendage Flow Velocity as a Risk of Thromboembolic Events After Catheter Ablation of Atrial Fibrillation","authors":"Shintaro Yamagami,&nbsp;Satoshi Shizuta,&nbsp;Munekazu Tanaka,&nbsp;Shushi Nishiwaki,&nbsp;Takanori Aizawa,&nbsp;Akihiro Komasa,&nbsp;Takashi Yoshizawa,&nbsp;Tetsuma Kawaji,&nbsp;Chihiro Ota,&nbsp;Naoaki Onishi,&nbsp;Yasuhiro Sasaki,&nbsp;Mitsuhiko Yahata,&nbsp;Kentaro Nakai,&nbsp;Mamoru Hayano,&nbsp;Tetsushi Nakao,&nbsp;Koji Hanazawa,&nbsp;Koji Goto,&nbsp;Takahiro Doi,&nbsp;Toshihiro Tamura,&nbsp;Koh Ono,&nbsp;Takeshi Kimura","doi":"10.1002/joa3.70233","DOIUrl":"https://doi.org/10.1002/joa3.70233","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Reduced left atrial appendage flow velocity (LAAFV) on transesophageal echocardiography (TEE) is recognized as a predictor of thromboembolic events (TEs) in patients with atrial fibrillation (AF). However, its long-term prognostic value following AF ablation remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We retrospectively evaluated 1521 patients undergoing AF ablation who underwent preprocedural TEE. Patients were categorized into two groups based on LAAFV: reduced (≤ 21.4 cm/s, <i>n</i> = 99) and preserved (&gt; 21.4 cm/s, <i>n</i> = 1422). The primary outcome was TEs. Secondary outcomes included arrhythmia recurrence and major adverse cardiovascular events (MACEs), defined as a composite of all-cause death, stroke, major bleeding, and heart failure hospitalization, as well as individual components and cardiovascular mortality. Over a mean follow-up of 49 ± 32 months, TEs occurred in 19 patients (1.2%). The 5-year cumulative incidence of TEs was significantly higher in the reduced LAAFV group (6.7% vs. 0.9%, <i>p</i> &lt; 0.0001), despite a lower rate of anticoagulation discontinuation (20.1% vs. 57.1%, <i>p</i> &lt; 0.0001). Multivariable analysis identified reduced LAAFV as an independent predictor of TEs. It was also associated with higher risks for all secondary endpoints.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Reduced preprocedural LAAFV is associated with adverse long-term clinical outcomes after AF ablation, including a significantly increased risk of thromboembolic events.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"41 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.70233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Arrhythmia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1